However, in GC patients, SATB1 was significantly correlated with advanced (stage III/IV) TNM stage (280 patients; pooled OR: 2.77, 95% CI 1.69–4.56, p < 0.0001), advanced(T3/T4) T stage (447 patients; pooled OR: 2.29, 95% CI 1.51–3.46, p < 0.0001), lymph node metastasis (450 patients; pooled OR: 2.87, 95% CI 1.88–4.37, p < 0.0001) and poor tumor differentiation (298 patients; pooled OR: 1.76, 95% CI 1.05–2.94, p = 0.03). The gene discussed is SATB1; the disease is gastric cancer.